Expression of EZH2 and Ki-67 in Colorectal Cancer and Associations with Treatment Response and Prognosis

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Sep 24

PMID 19773751

Citations 80

Authors

O Fluge

K Gravdal

E Carlsen

B Vonen

K Kjellevold

S Refsum

R Lilleng

T J Eide

T B Halvorsen

K M Tveit

A P Otte

L A Akslen

O Dahl

Affiliations

Soon will be listed here.

Abstract

Background: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation.

Methods: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised study, and treated with surgery alone or surgery followed by adjuvant chemotherapy.

Results: EZH2 expression was significantly related to increased tumour cell proliferation, as assessed by Ki-67 expression. In colon cancer, strong EZH2 expression (P=0.041) and high proliferation (>or=40%; P=0.001) were both associated with better relapse-free survival (RFS). In contrast, no such associations were found among rectal cancers. High Ki-67 staining was associated with improved RFS in colon cancer patients who received adjuvant chemotherapy (P=0.001), but not among those who were treated by surgery alone (P=0.087). In colon cancers stage III, a significant association between RFS and randomisation group was found in patients with high proliferation (P=0.046), but not in patients with low proliferation (P=0.26). Multivariate analyses of colon cancers showed that stage III (hazard ratio (HR) 4.00) and high histological grade (HR 1.80) were independent predictors of reduced RFS, whereas high proliferation indicated improved RFS (HR 0.55).

Conclusion: Strong EZH2 expression and high proliferation are associated features and both indicate improved RFS in colon cancer, but not so in rectal cancer.

Citing Articles

A comprehensive analysis of the prognostic value, expression characteristics and immune correlation of MKI67 in cancers.

Pan X, Wei C, Su J, Fang M, Lin Q, Qin Y Front Immunol. 2025; 16:1531708.

PMID: 40070823 PMC: 11894575. DOI: 10.3389/fimmu.2025.1531708.

Potential neuroendocrine differentiation in poorly differentiated colorectal adenocarcinoma: A hidden trait?.

Rong Y, Kato I, Okubo N, Tsuyuki S, Katsuta E, Kobayashi N Mol Clin Oncol. 2024; 21(6):91.

PMID: 39421232 PMC: 11484215. DOI: 10.3892/mco.2024.2789.

Endoscopic Resection of Stage T1 Colorectal Adenocarcinoma Followed by Surgical Intervention: a Single-center Retrospective Study.

Zhang D, Chen L, Wu J J Gastrointest Cancer. 2024; 55(4):1598-1606.

PMID: 39215956 PMC: 11464598. DOI: 10.1007/s12029-024-01109-4.

Characterisation of colorectal cancer by hierarchical clustering analyses for five stroma-related markers.

Ito S, Koshino A, Wang C, Otani T, Komura M, Ueki A J Pathol Clin Res. 2024; 10(4):e12386.

PMID: 38890810 PMC: 11187867. DOI: 10.1002/2056-4538.12386.

The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review.

Smorodin E, Chuzmarov V, Veidebaum T Curr Oncol. 2024; 31(4):1994-2023.

PMID: 38668052 PMC: 11049198. DOI: 10.3390/curroncol31040149.

References

Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyama G, Shimamoto F . Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol. 1999; 16(1):55-64. DOI: 10.3892/ijo.16.1.55. View

De Gramont A, Tournigand C, Andre T, Larsen A, Louvet C . Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol. 2007; 34(2 Suppl 1):S37-40. DOI: 10.1053/j.seminoncol.2007.01.004. View

Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham D, Fisher E . Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988; 80(1):30-6. DOI: 10.1093/jnci/80.1.30. View

van der Vlag J, Otte A . Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet. 1999; 23(4):474-8. DOI: 10.1038/70602. View

Collett K, Eide G, Arnes J, Stefansson I, Eide J, Braaten A . Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006; 12(4):1168-74. DOI: 10.1158/1078-0432.CCR-05-1533. View

Salminen E, Palmu S, Vahlberg T, Roberts P, Soderstrom K . Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer. World J Gastroenterol. 2005; 11(21):3245-9. PMC: 4316056. DOI: 10.3748/wjg.v11.i21.3245. View

Laurie J, MOERTEL C, Fleming T, Wieand H, Leigh J, Rubin J . Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989; 7(10):1447-56. DOI: 10.1200/JCO.1989.7.10.1447. View

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-51. DOI: 10.1056/NEJMoa032709. View

Bachmann I, Halvorsen O, Collett K, Stefansson I, Straume O, Haukaas S . EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2005; 24(2):268-73. DOI: 10.1200/JCO.2005.01.5180. View

10.

MOERTEL C, Fleming T, Macdonald J, Haller D, Laurie J, Goodman P . Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990; 322(6):352-8. DOI: 10.1056/NEJM199002083220602. View

11.

Baak J, Gudlaugsson E, Skaland I, Hui Ru Guo L, Klos J, Lende T . Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers. Breast Cancer Res Treat. 2008; 115(2):241-54. DOI: 10.1007/s10549-008-0126-y. View

12.

Brown D, Gatter K . Ki67 protein: the immaculate deception?. Histopathology. 2002; 40(1):2-11. DOI: 10.1046/j.1365-2559.2002.01343.x. View

13.

Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegard J, Stenling R . Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer. 1999; 79(3-4):577-81. PMC: 2362413. DOI: 10.1038/sj.bjc.6690091. View

14.

Allegra C, Paik S, Colangelo L, Parr A, Kirsch I, Kim G . Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003; 21(2):241-50. DOI: 10.1200/JCO.2003.05.044. View

15.

Bracken A, Pasini D, Capra M, Prosperini E, Colli E, Helin K . EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003; 22(20):5323-35. PMC: 213796. DOI: 10.1093/emboj/cdg542. View

16.

Bryant R, Cross N, Eaton C, Hamdy F, Cunliffe V . EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate. 2007; 67(5):547-56. DOI: 10.1002/pros.20550. View

17.

Chen H, Rossier C, Antonarakis S . Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics. 1996; 38(1):30-7. DOI: 10.1006/geno.1996.0588. View

18.

Dahl O, Fluge O, Carlsen E, Wiig J, Myrvold H, Vonen B . Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol. 2009; 48(3):368-76. DOI: 10.1080/02841860902755244. View

19.

Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V . Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene. 2004; 23(34):5759-69. DOI: 10.1038/sj.onc.1207706. View